Moreover, over the past three years (2020-2022), the keywords Immunotherapy, tumor microenvironment, prognosis, Immunosuppression, and PD-L1 have been consistently prominent, indicating that they likely reflect the current research focus on Treg in BC. This evidence concerns the gene CD274 and neoplasm.